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Abstract 
In recent years, antimicrobial drug resistance has become widespread and thus triggered 
an ever-growing need for the development of new, efficacious drug treatments. As an 
antimicrobial drug is developed, its mechanism of action is often identified before it 
becomes a potential candidate for clinical use. One potential method for identifying 
mechanism of action is chemical mutagenesis, in which induction of drug-resistant 
populations is followed by whole-genome sequencing of several clonal isolates. The 
subsequent observation of identical point mutations in the same gene across multiple 
drug-resistant populations can indicate a likely molecular target. However, this technique 
lacks the capacity to facilitate speedy and robust elucidation of the mechanism of action 
of experimental compounds, indicating a need for improved methods to enhance the 
efficiency of high-throughput drug target identification. In this work, a novel technique 
utilizing double chemical mutagenesis was developed in order to quickly induce the high 
levels of resistance indicative of specific resistance in the apicomplexan parasite 
Toxoplasma gondii. This technique is being used to identify drug targets in experimental 
compound, SW33, that has shown efficacy against T. gondii.  
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Introduction 
 The microbial infections caused by bacteria, viruses, and parasites are a leading 
cause of death worldwide [1,2]. Although there are currently a wide variety of treatments 
for microbial infections, the widespread use of antimicrobial drugs has led to 
unprecedented rates of resistance [3]. In fact, the World Health Organization has reported 
that combating drug resistance is one of the most important aspects of maintaining global 
public health [3]. During the drug development process, experimental compounds are 
first tested to in vitro then in vivo to determine their capability of fighting infections. The 
compounds that show efficacy in these conditions have the potential for clinical use. 
However, before they can move to pre-clinical trials, the way they function inside the 
cell, termed mechanism of action (MOA), is usually determined. It is important to 
elucidate the MOA as it can demonstrate that an antimicrobial drug is nontoxic; ideal 
drugs will target pathogens while leaving human cells unharmed. Additionally, 
elucidating the MOA can provide insight into the best best way to modify compounds to 
improve efficacy and ways to optimize combinational drug therapy.   
 The MOA of many antimicrobials is through the binding of a specific protein, 
termed the drug target, which renders the protein inactive. One of the ways that microbes 
develop resistance to drugs is through the development of mutations in the drug target 
which prevent the antimicrobial compound from binding. One method to elucidate MOA 
is through the utilization of this natural process. In the process of chemical mutagenesis, a 
chemical mutagen is applied to a large number of microbes to induce a specific number 
of mutations. An experimental compound is then applied to the mutant microbes at 
various concentrations and resistant populations are clonally isolated. Next generation 
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sequencing (NGS) is then performed and mutations in the same gene across several 
resistant microbes indicates a potential drug target. The mutant allele is then transfected 
into wild-type microbes and, if resistance is observed, it is likely the drug target has been 
identified. Further tests can then be performed to verify the correct identification of the 
drug target, including in silico drug-binding assays and cocrystallization of the protein 
with bound drug.   
A current problem with chemical mutagenesis is that often times only low levels 
of resistance is observed. This can potentially lead to the false-identification of a drug 
target because, during the acquisition of antimicrobial resistance, low levels of resistance 
can be indicative of general fitness advantages while high resistance is generally 
associated with mutations in the drug target. Thus, when attempting to identify mutations 
in the gene encoding the drug target (as needed for MOA identification), it is ideal to 
demonstrate high levels of resistance. In order to do this, a novel method of double 
chemical mutagenesis was developed. 
 In the process of double mutagenesis, drug-targeted organisms are chemically 
mutagenized, selected for under drug pressure, then mutagenized a second time and 
selected for under still higher concentrations of experimental compound. This process is 
designed to take advantage of a trait in observed in microbes with high-antimicrobial 
resistance: a single mutation in the drug target may only induce low levels of resistance 
where subsequent mutations may confer high levels of resistance. Thus, a double 
mutagenesis is specifically designed to induce and select for single mutations in the drug-
targeted gene with the first chemical mutagenesis then induce subsequent mutations in 
the gene with the second chemical mutagenesis.  
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 In this work, the ubiquitous parasite Toxoplasma gondii was utilized. T. gondii 
makes an ideal target for drug development because it infects nearly one third of the 
world’s population, causes devastation to pregnant woman and the immunocompromised, 
and there is currently no cure for the chronic stage [4,5,6]. Additionally, the current 
treatments for toxoplasmosis, pyrimethamine and sulfadiazine (Figure 1), are toxic to the 
host and, thus, the development of tolerable treatments is imperative [7]. Furthermore, the 
genetic similarities between T. gondii and the causative agent of malaria, Plasmodium 
falciparum, result in drugs effective against one of these pathogenic parasites often being 
effective against the other [8,9].  
 To test the efficacy of double mutagenesis, we utilized the folate-pathway-
inhibitor pyrimethamine as it has a known drug target. Thus, after performing double 
mutagenesis, we were able to examine the accuracy of double mutagenesis by comparing 
the experimentally identified drug target to the known target. We then used mutagenesis 
to determine the drug target of the antioxoplasma compound, SW33. Following four 
separate mutagenesis experiments, we observed that double mutagenesis was unable to 
effectively confer resistance to SW33 in T. gondii. These results potentially suggest the 
drug target of SW33 is unable to function when mutations are introduced.  This could 
indicate a drug target that is encoded in the apicoplast genome, as single mutations in 
these genes result in nonviable parasites [10]. Additionally, SW33 may function as an 
ionophore as previous works have demonstrated that mutagenesis is an ineffective tool 
for identifying their MOA [10]. Future experiments will need to be performed in order to 
test for the possibility of an apicoplast drug target and ionophore functions. Because 
apicioplasts are unique to apicomplexans, the potential for SW33 to target this plastid 
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would make it a promising drug for clinical use as it would be nontoxic to humans, thus 
giving it an advantage over current treatments.   
  
 
 
 
 
 
 
 
Figure 1: Structures of Pyrimethamine and Sulfadiazine 
The current treatments for toxoplasmosis, sulfadiazine and pyrimethamine, both have affinity for human proteins 
and are therefore toxic. A) Pyrimethamine is the current treatment for acute toxoplasmosis. It functions by 
targeting DHFR which inhibits the folate pathway and pyrimethamine synthesis. B) Sulfadiazine also targets the 
folate pathway.  
Sulfadiazine Pyrimethamine 
A B 
Figure 1 
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Materials and Methods 
Parasites and media 
T. gondii parasites were maintained through serial passage in human foreskin fibroblasts 
(HFF) using DMEM media supplemented with 10% bovine calf serum as previously 
described [11]. All parasite strains are derived from Type 1 RH T. gondii strain isolated 
from a patient in 1939 [12]. Conditioned media was generated by infecting 175 cm2 
flasks confluent with HFF with 7mL of media confluent with RH parasites.  
 
Plaque Assays 
Plaque assays were performed as previously described [13]. Briefly, 10 flasks containing 
confluent HFF cells infected with T. gondii were cultured in 25 cm2 flasks. Nine of the 
flasks were treated with varying concentrations of N-ethyl-N-nitrosurea (ENU) (1.25 
mM, 2.5 mM, 5 mM), Ethylmethane sulfonate (EMS) (8mM, 10mM, 12mM), and a 
combination of both EMS and ENU, respectively (6mM/3mM, 4mM/2mM, 2mM/1mM) 
for four hours while the 10nth flask acted as an untreated control. Media was removed 
and the monolayer was rinsed 3x with 1x PBS. The monolayer was then scraped, 
homogenized, and syringe filtered. 1000 parasites from each flask were transferred to 
new flasks. After 1 week, plaques were counted and percent death was determined. 
 
Double Chemical Mutagenesis  
Chemical mutagenesis was performed using both pyrimethamine and SW33, separately, 
as previously described [13]. Briefly, a mixture of EMS (5mM) and ENU (3.5mM) were 
added to 11 175 cm2 flasks confluent with RH strain parasites. Following 4 hours of 
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incubation, the media was removed and the monolayer was rinsed 3x with 1x PBS. The 
monolayer was then scraped, homogenized, syringe filtered, and passed to 175 cm2 flasks 
confluent with HFF. After 24 hours, the flasks were then treated with 3.2µM, 4.26µM, 
6.39µM 10.65µM, and 21.3µM of experimental compound SW33 or pyrimethamine. 
Following four days of treatment, the monolayers were homogenized, syringe filtered, 
and passed to 25 cm2 flasks where treatment was continued for 10 days. Parasites viable 
at the highest SW33 concentration were subjected to a second round of EMS and ENU 
before selection under .26µM, 6.39µM 10.65µM, 21.3µM, 31.95µM SW33.  
 
Clonal Isolation 
Resistant parasites were clonally isolated using serial dilution in 96-well plates 
containing conditioned DMEM media. Singular plaques were identified through 
fluorescence microscopy. Following five days of plaque formation, contents of single-
plaque wells were transferred to 25 cm2 flasks confluent with HFF. 
 
Half-maximal inhibitory concentration (IC50) analysis 
96-well plates confluent with HFF were infected with 2,000 parasites per well. Serial 
dilutions of SW33 were administered two days after infection. IC50 concentrations were 
determined to be the concentrations of SW33 that reduced fluorescence by 50% using 
flasks containing 1% DMSO as control. The IC50 of SW33 was determined to be 2.13 µM 
in previously unpublished works.  
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Results 
Pyrimethamine double-mutagenesis optimization 
To test the efficacy of double mutagenesis, pyrimethamine was utilized as the 
experimentally found drug target can be compared to the known drug target. Following 
the first mutagenesis experiment, the most drug-resistant mutant was three times more 
resistant (4.5 µM) than WT (1.5 µM). After a second round of mutagenesis, the most 
resistant mutant exhibited eight times more resistance than WT (figure 2). As DHFR is 
the known target of pyrimethamine, the DHFR gene was PCR amplified in the resistant 
mutant in order to compare the experimentally found drug target to the known drug 
target. Interestingly, the sequenced DHFR showed no mutations.  
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Figure 2: Observed Resistance of Parasites Before and After Double Mutagenesis 
Double Mutagenesis introduced an 8-fold resistance to pyrimethamine compared to WT. 
However, Sanger Sequencing of the DHFR of the most resistant clone showed no mutations.  
Figure 2 
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Figure 3 
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Figure 3: Percent death caused by EMS and ENU 
Plaque assays were performed using various concentrations of EMS, ENU, and a 
combination of both EMS and ENU. A combination of EMS and ENU was chosen 
at 5mM/2.5mM, respectively, as the concentrations that yielded 90% death. For 
the mutagenesis using solely EMS, a concentration of 10mM was chosen. 
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SW33 double mutagenesis 
ENU and EMS are often used in chemical mutagenesis due to their ability to induce a 
controlled amount of single nucleotide variances (SNVs)[13]. However, both mutagens 
have distinct mutagenic profiles [13]. Thus, EMS and ENU were administered 
concurrently, in order to induce a wide range of distinct mutations. Plaque assays using 
both ENU and EMS indicate that 5mM EMS with 2.5mM ENU induce 90% killing as 
determined using a best fit line (figure 3). This is the percent killing recommended to 
induce one SNV per million base pairs as previously demonstrated [13]. Double chemical 
mutagenesis was performed four separate times and drug selection above 4.26µM 
consistently killed all parasites. In previous mutagenesis experiments, resistant parasites 
were able to be maintained under constant drug selection above 50x IC50 [13]. Following 
mutagenesis, SW33 concentrations over 3.2 µM (1.5x IC50) decimated the mutant 
parasite populations. This unique result indicates that resistance may be difficult or 
impossible to induce. A single flask of mutant parasites (population D) was able to be 
maintained at 4.26 µM (2x IC50) after being treated for fourteen days with SW33, 
followed by removal of drug treatment for approximately thirty days, then resumed 
treatment with SW33.  
After four double chemical mutageneses, there were four distinct parasite 
populations viable at 3.2µM SW33 and a single population viable at 4.2µM (population 
group D, Table 1). Clonal isolation was performed, and three clones were isolated from 
each population resulting in fifteen clonal isolates. Half-maximal inhibitory 
concentrations were derived for eight of the fifteen clonal isolates (table 1). Although 
only low levels of resistance was observed, we are currently isolating DNA and sending 
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samples to NGS. The next procedure will be to perform bioinformatics analysis on the 
raw NGS data. 
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Figure 4: Induced Resistance to SW33 
While mutagenesis was able to induce mutations that conferred resistance to SW33, only 1.76x 
resistance was observed. This unique result may be indicative of an apicoplast-gene target or 
ionophore activity.   
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Discussion 
 The pyrimethamine optimization yielded eight times more resistance than WT 
parasite but no mutations were found in the DHFR. While this result is interesting, 
limited funds hindered our ability to further examine the genome using NGS . However, 
future experiments may include the examination of these parasites, as their resistance to 
pyrimethamine through other means besides DHFR mutations may provide insight into 
the potential for the development of clinical resistance in a similar fashion. Despite an not 
finding the correct target, we believe double mutagenesis has viability for determining 
MOA as high resistance was induced and future double mutageneses will include the 
isolation of several clonal isolates with which to compare mutations. Sequencing multiple 
clonal isolates and comparing their mutations will greatly improve the likelihood of 
correctly identifying the drug target.  
Given the lack of concurrent EMS and ENU applications in the literature, a 
concentration that resulted in 90% killing was used in order to induce one SNV per 
megabase (approximately 70 mutations per parasite). The results of the plaque assays 
indicate that 5mM EMS and 2.5mM ENU lead to 90% death, as determined using a best 
fit line (Figure 2). Because this concurrent treatment has never been administered, it is 
unclear whether these concentrations induce one SNV per megabase; further sequencing 
results are needed. There is a possibility that using both EMS and ENU simultaneously 
leads to deleterious outcomes not present when used separately. Current SW33 
mutagenesis experiments are being performed with EMS (no ENU) in order to address 
this concern.  
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 Despite four separate double mutagenesis experiments, the most resistant clonal 
isolate was just 1.76x more resistant than WT. Population D was able to remain viable at 
the highest SW33 treatment, 2x IC50 concentrations. Interestingly, isolates from 
population group D do not show the highest resistance. Low levels of resistance may be 
the result of the drug target being an essential gene that cannot be mutated. This is 
characteristic of genes encoding in the apicoplast as they are unable to be mutated and 
still produce viable parasites [14]. Thus, there is a possibility that the drug target is a 
protein synthesized in the apicoplast. This would be ideal as apicoplasts are unique to 
apicomplexans and therefore SW33 would likely be nontoxic to humans. If the drug 
target of SW33 is an essential gene whose mutations invariably cause parasite death, it is 
unlikely that mutagenesis will lead to the elucidation of the mechanism of action. The 
exception to this would be if mutations caused changes in gene expression, as 
upregulation of the drug target would result in observed resistance.  
While these results are not ideal in terms of robustly elucidating mechanism of 
resistance, they may imply a potential difficulty or inability of the T. gondii to gain 
resistance to SW33. If true, this would make SW33 a strong candidate for clinical use. 
Further experiments should include the use of double mutagenesis on Plasmodium 
falciparum using SW33. Although double chemical mutagenesis is proving unsuccessful 
with SW33, it may still be a valuable lab technique. Mutagenesis can not only be used to 
find drug targets but can provide valuable information into the ease of which an organism 
may develop antimicrobial resistance to a specific drug. This information can then be 
used as a metric to determine the best drugs for clinical trials as the drugs which parasites 
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have the most difficulty building resistance to would potentially be the best drugs for 
clinical use.   
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